HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/ NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT

Bone Marrow Transplantation

Volumn 43, Issue 9, 2009, Pages 693-699

  Nguyen, S ^a,b   Beziat, V ^a,b   Dhedin, N ^a   Kuentz, M ^c   Vernant, J P ^a   Debre, P ^a,b   Vieillard, V ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; CD94 ANTIGEN; GAMMA INTERFERON; HLA E ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER RELAPSE; CANCER SURVIVAL; CELL MATURATION; CELL PROTECTION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HAPLOTYPES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNE SYSTEM; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 67349221158     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.380     Document Type: Article

References (34)

1. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274.
2. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol Lett 2005; 100: 7-13.
3. Hallet WH, Murphy WJ. Positive and negative regulation of Natural Killer cells: Therapeutic implications. Semin Cancer Biol 2006; 16: 367-382.
4. López-Botet M, Llano M, Navarro F, Bellón T. NK cell recognition of non-classical HLA class I molecules. Semin Immunol 2000; 12 109-119.
5. Long EO, Rajagopalan S. HLA class I recognition by killer cell Ig-like receptors. Semin Immunol 2000; 12: 101-118.
6. Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795-799.
7. Freud AG, Caligiuri MA. Human natural killer development. Immunol Rev 2006; 214: 56-72.
8. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136 4480-4486.
9. Cooper MA, Felmiger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 11: 633-640.
10. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, Rouas-Freiss N et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: Immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005; 105: 4135-4142.
11. Nguyen S, Kuentz M, Vernant JP, Dhedin N, Bories D, Debré P et al stem-cell transplantation. Leukemia 2008; 22: 344-352.
12. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.
13. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370-4376.
14. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann TL et al A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 2007; 110: 578-586.
15. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, LópezBotet M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998; 95: 5199-5204.
16. Lanier LL. Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 1998; 92: 765-707.
17. MaImberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K et al. IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2Adependent mechanism. J Clin Invest 2002; 110: 1515-1523.
18. Gustafson KS, Ginder GD. Interferon-gamma induction of the human leukocyte antigen-E gene is mediated through binding of a complex containing STAT1alpha to a distinct interferon-gamma-responsive element. J Biol Chem 1996; 271: 20035-20046.
19. Marusina AI, Kim DK, Lieto LD, Borrego F, Coligan JE. GATA-3 is an important transcription factor for regulating human NKG2A gene expression. J Immunol 2005; 174: 2152-2159.
20. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998; 187 13-818.
21. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
22. Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A et al. Expression and release of HLA-E by melanoma cells and melanocytes: Potential impact on the response of cytotoxic effect cells. J Immunol 2006; 177: 3100-3107.
23. Tomasec P, Brand VM, Rickards C, Powell MB, McSharry BP, Gadola S et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287: 1031.
24. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M et al. Cutting edge: The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000; 164: 5019-5022.
25. Cerboni C, Mousavi-Jazi M, Wakiguchi H, Carbone E, Kärre K, Söderström K. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol 2001; 31: 2926-2935.
26. Moser JM, Gibbs J, Jensen PE, Lukacher AE. CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. Nat Immunol 2002; 3: 189-195.
27. Antin JH, Ferrara JL. Cytokine dysregulation and acute graftversus- host disease. Blood 1992; 80: 2964-2968.
28. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of Interferon-gamma in GVHD and GVL. Cell Mol Immunol 2005; 2: 323-329.
29. Valés-Gómez M, Reyburn HT, Erskine RA, López-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/ NKG2-C to HLA-E. EMBO J 1999; 18: 4250-4260.
30. Di Santo JP. Natural killer cell developmental pathways: A question of balance. Annu Rev Immunol 2006; 24: 257-286.
31. Yoon SR, Chung JW, Choi I. Development of natural killer cells from hematopoietic stem cells. Mol Cells 2007; 24: 1-8.
32. Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Elminger G. Role of KIR ligand incompatibility in hematopoietic stem-cell transplantation using unrelated donors. Blood 2004; 103: 2860-2861.
33. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stem M, Kühne T et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18: 1835-1838.
34. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.